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ABSTRACT
Background
Outbreaks of meningococcal meningitis (meningitis caused by Neisseria meningitidis) are a
major public health concern in the African ‘‘meningitis belt,’’ which includes 21 countries from
Senegal to Ethiopia. Of the several species that can cause meningitis, N. meningitidis is the most
important cause of epidemics in this region. In choosing the appropriate vaccine, accurate N.
meningitidis serogroup determination is key. To this end, we developed and evaluated two
duplex rapid diagnostic tests (RDTs) for detecting N. meningitidis polysaccharide (PS) antigens
of several important serogroups.
Methods and Findings
Mouse monoclonal IgG antibodies against N. meningitidis PS A, W135/Y, Y, and C were used
to develop two immunochromatography duplex RDTs, RDT1 (to detect serogroups A and
W135/Y) and RDT2 (to detect serogroups C and Y). Standards for Reporting of Diagnostic
Accuracy criteria were used to determine diagnostic accuracy of RDTs on reference strains and
cerebrospinal fluid (CSF) samples using culture and PCR, respectively, as reference tests. The
cutoffs were 10
5 cfu/ml for reference strains and 1 ng/ml for PS. Sensitivities and specificities
were 100% for reference strains, and 93.8%–100% for CSF serogroups A, W135, and Y in CSF.
For CSF serogroup A, the positive and negative likelihood ratios (6 95% confidence intervals
[CIs]) were 31.867 (16.1–63.1) and 0.065 (0.04–0.104), respectively, and the diagnostic odds ratio
(6 95% CI) was 492.9 (207.2–1,172.5). For CSF serogroups W135 and Y, the positive likelihood
ratio was 159.6 (51.7–493.3) Both RDTs were equally reliable at 25 8C and 45 8C.
Conclusions
These RDTs are important new bedside diagnostic tools for surveillance of meningococcus
serogroups A and W135, the two serogroups that are responsible for major epidemics in Africa.
The Editors’ Summary of this article follows the references.
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It is estimated that annually over one million cases of
meningitis are caused by three bacterial species: Neisseria
meningitidis (also termed meningococci, the cause of menin-
gococcal meningitis or disease), Streptococcus pneumoniae, and
Haemophilus inﬂuenzae b [1]. Together, these organisms cause
substantial morbidity and mortality globally. N. meningitidis is
the cause of epidemic meningitis associated with high
mortality worldwide, but more than 50% of all of these
meningococcal meningitis cases are reported from sub-
Saharan Africa’s ‘‘meningitis belt,’’ which extends from
Senegal to Ethiopia and includes 21 countries with a total
at-risk population of 250 million [1]. Severe annual outbreaks
of meningococcal meningitis are reported in this region, and
incidence of the disease may be as high as 1,000 per 100,000
inhabitants [3–5]. Outbreaks occurring during the past ten
years (1995–2004) have resulted in almost 700,000 cases and
60,000 deaths [5].
N. meningitidis polysaccharide (PS) serogroup A is respon-
sible for major epidemics in Africa, but the recent change in
epidemiological pattern due to the emergence of serogroup
W135 as an epidemic strain is a cause of particular concern
[6–8]. The WHO strategy for controlling epidemic meningo-
coccal disease in this region is based on (i) early and accurate
detection and (ii) rapid implementation of mass vaccination
using an appropriate polysaccharide (PS) vaccine [9]. How-
ever, the response to epidemic meningococcal disease in
Africa is hindered by delays in (or even the lack of)
identiﬁcation of the causal agent and by the scarcity and
high cost of polyvalent vaccines. Decision-makers at country
level in the meningitis belt need to make use of the best
epidemiological and laboratory evidence for choosing the
most appropriate vaccine. The implementation of alert and
epidemic thresholds and of a decisional tree, based on
reliable identiﬁcation of the aetiological agent for selection
of the most appropriate vaccine, is recommended [1,10].
The gold standard diagnostics for meningococci are the
classic culture with subsequent identiﬁcation of serogroup
using speciﬁc antisera and the multiplex PCR method [11]. In
the sub-Saharan countries, neither of these two tests is
available outside the capitals, large cities, or reference
laboratory settings [12]. The old nonculture tests (leucocyte
cell count and Gram stain microscopy), although rapid and
cheap, cannot identify the serogroup responsible for a given
outbreak to guide the choice of vaccine. Currently, latex
agglutination tests (LATs) are most widely used to identify
meningococcal PS serogroups in the cerebrospinal ﬂuid (CSF)
of patients. The Pastorex (Bio-Rad) kit for detecting
serogroup A, B, C, and W135/Y has been evaluated for
serogroup A and W135 under reference laboratory condi-
tions [13] and in a district laboratory in Niger [14]. The
sensitivity and speciﬁcity are good, ranging from 84.9% to
88% and from 93% to 97.4%, respectively. This kit does not,
however, differentiate between serogroups W135 and Y, and
its performance under ﬁeld conditions lacking basic labo-
ratory equipment is not known. Furthermore, this kit
requires cold storage, and its high cost does not allow its
use in every district or health care centre. Together these
difﬁculties explain the consistent failure of outbreak aetiol-
ogy identiﬁcation and the lack of proper case management
(resulting in inadequate antimicrobial treatment), which are
main causes of death due to meningococcal disease.
In view of this situation, we therefore aimed to develop and
evaluate the diagnostic accuracy of easy-to-perform rapid
diagnostic tests (RDTs) for the speciﬁc and sensitive detection
of meningococcal PS serogroup antigens that can be used in
resource-poor countries, especially near rural populations
and at the patient’s bedside.
Methods
Standard Diagnostic Methods
Culture and PCR were used as gold-standard diagnostic
methods. They were performed by two trained technicians
according to reference techniques routinely used at the
CERMES (National Reference Centre for Meningitis, Niamey,
Niger) [12].
For culture, CSF specimens were drawn from clinically
suspected cases of meningitis according to the national
guidelines of the Ministry of Health. The specimens were
cultured on blood agar and chocolate agar (at 37 8C with 5%
CO2) and the serogroups of the N. meningitidis isolates were
determined by agglutination with serogroup-speciﬁc antisera
(Bio-Rad, Marnes-la-Coquette, France, and DIFCO, Detroit,
Michigan, United States).
Multiplex PCR was performed on freeze-boiled CSF
samples to amplify the crgA gene of N. meningitidis [11], the
lytA gene of S. pneumoniae [15], and the bexA gene of H.
inﬂuenzae [16]. For genogrouping of meningococcus-positive
specimens, a second PCR was performed to amplify the siaD
gene for serogroups B, C, Y, and W135 and the orf-2 of the
mynB gene for serogroup A [11]. Specimens testing positive
for H. inﬂuenzae type b were conﬁrmed by ampliﬁcation of the
cap gene [16]. PCR was performed in a Primus 96 thermo-
cycler (MWG Biotech, Ebersberg, Germany). The detection
threshold for PCR was 1–10 bacteria per assay, as shown by
CSF samples spiked with serial 10-fold dilutions of reference
strain suspensions of N. meningitidis serogroups A, B, C, Y and
W135, S. pneumoniae, and H. inﬂuenzae b.
A ‘‘negative’’ CSF sample was negative by culture and PCR
for N. meningitidis, S. pneumoniae, and H. inﬂuenzae.A
‘‘conﬁrmed’’ CSF sample was a specimen that tested positive
by culture and/or PCR for N. meningitidis, S. pneumoniae, or H.
inﬂuenzae.
Development of RDTs for the Detection of Meningococcal
PS Antigen
Anti-N. meningitidis monoclonal antibodies (Mabs) were
developed at the Institut Pasteur (Paris, France). Biozzi BP/2
mice were immunized with four different PS conjugates (A,
W135, C, and Y). Conventional fusion and ELISA screening of
resulting hybridomas were carried out and IgG Mabs were
selected on the basis of high speciﬁcity and afﬁnity for
puriﬁed A, W135, C, and Y PS. Conjugates and PS were kindly
provided by Sanoﬁ Pasteur. The selected Mabs were: K15–2
(anti-serogroup A IgG1, kappa chain); B6–1 (anti-serogroup C
IgG1, kappa chain); L14–7 (anti-serogroup Y IgG2b, kappa
chain); and C18–3 (anti-serogroup W135/Y IgG1, kappa
chain). Although we obtained Mab D20–19, which is speciﬁc
to serogroup W135 by ELISA, we did not use it because it
cross-reacts with serogroup Y when used in immmunochro-
matography. The four selected Mabs were conjugated to gold
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four monovalent one-step vertical ﬂow immunochromatog-
raphy dipsticks (N. meningitidis serogroups A, C, Y, and W135/
Y) were designed and optimized as previously described
[17,18], with Accuﬂow polyester (Schleicher & Schuell
Bioscience, Ecquevilly, France) used as the conjugate pad
[19]. Homologous Mabs directed against serogroups A, C, Y,
and W135/Y were sprayed onto the nitrocellulose at a high
concentration of 2 lg per centimeter line, to give a speciﬁc
capture line. As a control line for the capture of gold particles
conjugated with mouse Mab, goat anti-mouse IgG was sprayed
onto the nitrocellulose at a concentration of 0.8 lg/cm (ICN
Biomedicals, Aurora, Ohio, United States). The hybridomas
have been deposited at the Collection Nationale des Micro-
organismes (Institut Pasteur, Paris, France) and are available
upon request to Institut Pasteur.
Four monovalent dipsticks (serogroups A, W135/Y [i.e.,
detects both W135 and Y but does not distinguish between
them], C, and Y) were optimized and preliminary tests carried
out. They were assembled as two duplex dipsticks—RDT1 for
A and W135/Y and RDT2 for C and Y (see Figure 1)—for
evaluation by CERMES. The RDTs were stored at 4 8Ci na
moisture-proof bag until use. The test was carried out in 3 ml
disposable plastic tubes at 25 8C (air-conditioned laboratory),
and a volume of 150–200 ll of plain CSF or reference strain
suspension in PBS, pH 7.2 was used. After incubation of the
dipstick with its end in the sample for 10–15 min, the
chromatographic result was recorded. A negative result
consisted of a single upper pink control line, and a positive
result consisted of two pink lines, the upper control line and
the lower positive line.
Evaluation of Duplex RDTs
Sensitivity and speciﬁcity. The sensitivity and speciﬁcity of
each RDT were assessed by one trained technician.
Reference isolates of N. meningitidis (serogroups A, B, C,
W135, Y, and X), N. lactamica, S. pneumoniae, and H. inﬂuenzae b
were obtained from the 2003–2004 collection of strains of
CERMES and from the collection of the WHO Collaborating
Centre for meningococci (IMTSSA, Marseille, France) and
stored at  80 8C in brain-heart infusion supplemented with
10% glycerol. The bacteria were cultured on blood agar at 37
8C with 5% CO2 for 16 h. The colonies were suspended in
PBS, adjusted to a concentration of 10
8 cfu/ml (colony count
of serial dilutions plated on blood agar), and heat-killed for 2
ha t6 08C. Numbers and reference strains tested for
speciﬁcity were: 30 N. meningitidis of serogroup W135, 25
serogroup Y, 18 serogroup A, ten serogroup X, 11 serogroup
B, seven serogroup C, nine N. lactamica, ten S. pneumoniae, and
ten H. inﬂuenzae b. Numbers and strains tested for sensitivities
were: ten N. meningitidis of serogroup A, 30 serogroup W135,
25 serogroup Y, and seven serogroup C.
CSF samples were collected in 2003–2005 from patients in
Niger, before treatment, who were documented as suspected
of having meningitis; these samples were tested by the
reference standard tests (culture and/or multiplex PCR).
These samples were stored at  20 8C until use. Numbers and
strains tested for speciﬁcities were: 255 N. meningitidis of
serogroup A, 48 serogroup W135, 11 serogroup X, 30 S.
pneumoniae, 21 H. inﬂuenzae b, and 162 negative for N.
meningitidis/S. pneumoniae/H. inﬂuenzae b; and for sensitivities
255 N. meningitidis of serogroup A, 48 serogroup W135, and
four serogroup Y. No CSF of serogroup C was available.
Cutoff, reproducibility, and shelf life. The detection limit
(cutoff) of each RDT was determined on 10-fold dilutions of
reference N. meningitidis PS from the National Institute for
Biological Standards and Control (Hertfordshire, UK) for
serogroup C code 38/730, serogroup A code 98/722, serogroup
Y code 01/426, and serogroup W135 code 01/428, and for
calibrated reference meningococcal strains from the Man-
chester Medical Microbiology Partnership (Manchester, UK)
serogroup C code 11, serogroup A code 243594, and
serogroup W135 code M01.240070 and from CERMES,
serogroup Y code 477–03. Meningococcal strains were added
to and diluted in pooled negative CSF samples.
The reproducibility of the cutoffs was assessed by testing,
ten times simultaneously and using the same batch of RDTs,
calibrated suspensions (10
5 cfu/ml) of the reference menin-
gococcal serogroups A, W135, C, and Y.
To predict the shelf-life of our RDTs, we used the
accelerated stability method that consisted in storing the
assays for a time at elevated temperature [20]. RDT1 and
RDT2 were tested over a period of three weeks of exposure at
high temperature of 60 8C on serial dilutions of PS serogroup
A, W135, C and Y, twice per week. This accelerated stability
method is equivalent to two years of actual storage time at
room temperature (25 8C) [17]. In addition, as these RDTs are
intended to be used in the ﬁeld outside of air-conditioned
settings, we compared the reliability of the tests performed at
25 8C (air-conditioned room) and 45 8C (incubator), simulat-
ing normal room temperature in the Sahel during the
meningitis season.
Prospective Study
We compared the results obtained with PCR and RDT1
performed in a blind study by two different technicians, on
57 frozen CSF samples from patients with suspected
meningitis. These samples were collected, before treatment,
from patients in the Niamey and Maradi regions, from
January 15th to February 11th 2005 and were received at the
CERMES for aetiological diagnosis.
Statistics
The evaluation was performed according to the STARD
(Standards for Reporting of Diagnostic Accuracy) for new
assays [21].
We calculated the sensitivity (Se) of the RDTs, which is the
Figure 1. RDT Results by Serogroup
Results of RDT1 and RDT2 are shown for each N. meningitidis serogroup.
DOI: 10.1371/journal.pmed.0030337.g001
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Diagnosis of Meningococcal Meningitisproportion of specimens with the target disorder in which
the test result is positive; and the speciﬁcity (Sp), which is the
proportion of specimens without the target disorder in which
the test result is negative. The 95% conﬁdence intervals (CIs)
for Se and Sp were calculated [22].
We also calculated likelihood ratios (LR). The positive LR
(LRþ¼Se/[1 Sp]) indicates how many times a positive result
is more likely to be observed in specimens with the target
disorder than in those without the target disorder. The
negative LR (LR ¼[1   Se]/Sp) indicates how many times a
negative result is more likely to be observed in specimens
with the target disorder than in those without the target
disorder. The test is more accurate the more LR differs from
1. LRþ above 10 and LR  below 0.1 were considered
convincing diagnostic evidence [23]. The 95% CIs were
calculated for LRþ and LR  [24]. LRs were not determined
for a Se or Sp of 100%.
The diagnostic odds ratio (DOR), deﬁned as the ratio of the
odds of positive test results in specimens with the target
disorder relative to the odds of positive test results in
specimens without the target disorder, was calculated as
follows [25]:
DOR ¼ð Se=½1   Se Þ=ð½1   Sp =SpÞð 1Þ
The DOR does not depend on prevalence and its value
ranges from 0 to inﬁnity, with higher values indicating better
discriminatory test performance. The 95% CIs for DOR
values were calculated [26].
The positive predictive value (PPV) represents the pro-
portion of test-positive specimens that truly present the
target disorder, while the negative predictive value (NPV)
represents the proportion of test-negative specimens that
truly do not present the target disorder:
PPV ¼ð Prev3SeÞ=ðPrev3SeÞþð ½ 1   PrevÞ3½1   Sp Þ ð2Þ
and
NPV ¼ð ½ 1   PrevÞ3SpÞ=
ð½ð1   PrevÞ3Sp þ½ Prev3ð1   SeÞ Þ: ð3Þ
‘‘Prev’’ is the prevalence of the target disorder in the
population of specimens to which the test is applied. The
95% CIs for PPVs and NPVs were calculated [22].
Finally, we calculated the Cohen’s kappa (j) statistic [27] to
measure concordance between PCR and RDT in the
prospective blind study. j may range from 0 to 1, and a j
value higher than 0.8 is thought to reﬂecting almost perfect
agreement [28]. The 95% CIs for j were calculated according
to a method described by Fleiss [29].
Ethical Aspects
All specimens were collected as part of the routine clinical
management of patients, according to the national guidelines
in Niger. Consequently, informed consent was not sought and
approval from the national ethics committee was not
required.
Results
The diagnostic accuracy (based on STARD criteria) of the
RDTs was assessed from December 2004 to November 2005,
and was completed in February and March 2006.
Cutoff and Reproducibility
As no monospeciﬁc Mab against W135 could be obtained,
two duplex dipsticks were created: RDT1, for the detection of
serogroups A and W135/Y, and RDT2, for the detection of
serogroups C and Y and for discrimination between W135
and Y. The detection limits for the four serogroups were 1 ng
PS/ml and 10
5 cfu/ml of CSF. The cutoffs could be reproduced
ten times for each of the four serogroups tested (A, W135, C,
and Y), using calibrated suspensions (10
5 cfu/ml) of reference
strains.
No prozone phenomenon was observed with any of the
RDTs at higher concentrations of PS (1 lg/ml) and bacteria
(10
8 cfu/ml).
Sensitivities, Specificities, Likelihood Ratios, and Predictive
Values
The sensitivities and speciﬁcities, with 95% CI, of the two
RDTs with reference strains and documented CSF samples
are summarized in Table 1. The sensitivity of RDT2 for CSF
infected by serogroup C, a relatively rare serogroup in Africa,
was not determined due to a lack of CSF samples but we were
able to determine speciﬁcity. The speciﬁcity of the test for
serogroup Y was 100%, but the sensitivity still must be
accurately determined (all four CSF tested were positive).
For serogroup A identiﬁcation, LRþ was 31.867 (95% CI,
16.1–63.1) and LR  was 0.065 (95% CI, 0.04–0.104), and the
DOR was 492.9 (95% CI, 207.2–1,172.5). For serogroups W135
and Y, LRþwas 159.7 (95% CI, 51.7–493.3). It was not possible
to calculate the other LRs and DORs because either their Se
or their Sp was 100%.
The variations of NPV and PPV for the diagnosis of
serogroups A and W135, according to prevalence, were
determined using the Se and Sp for clinical CSF samples
(Figure 2). To diagnose the four serogroups (A, W135, C, and
Y), we propose an algorithm based on the combination in
series of RDT1 and RDT2. Figure 1 shows the results obtained
for both tests on each serogroup.
Shelf Life and Reliability
The results for RDT1 and RTD2 for the reference strains A,
W135, and C were not affected by storage for 3 wk at 60 8C.
For the serogroup Y, the test was stable for only 10 d at that
temperature. RDT1 and RDT2 were equally accurate whether
performed at ambient temperatures of 25 8Co r4 58C.
Comparative Prospective Study
PCR tests on 57 CSF samples from patients with suspected
bacterial meningitis received for aetiological diagnosis
showed that 20 samples contained N. meningitidis (17 of
serogroup A, two serogroup W135, and two serogroup X), 16
S. pneumoniae, four H. inﬂuenzae b; 16 samples tested negative
(Table 2). RDT1 identiﬁed 17 samples as positive for N.
meningitidis serogroup A, and two as positive for W135/Y.
There were two discordant results (serogroup A), giving an
overall concordance level of 96.5% (55/57) between the two
tests, and a Cohen’s j coefﬁcient of 0.92 (95% CI, 0.82–1.03).
Discussion
Because of the recent emergence of a new epidemic strain
of N. meningitidis, serogroup W135, strengthening the capacity
for epidemiologic and microbiologic surveillance and facil-
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Diagnosis of Meningococcal Meningitisitating faster mass vaccination are urgently needed for
effective prevention and control of epidemic meningococcal
disease in Africa. A rapid diagnostic assay for the identi-
ﬁcation of meningococci is also needed to ensure admin-
istration of the appropriate antimicrobial treatment, to
improve case management.
When hybridoma cell lines were screened by ELISA, one
speciﬁc anti-W135 Mab was obtained; however, when assessed
by immunochromatography (very high concentration of Mab
on the nitrocellulose), it cross-reacted with serogroup Y, so it
was not used. Previous IgG3 anti-W135 Mab has been
described by Tsang and colleagues [30], but its speciﬁcity
was assessed by ELISA and not by immunochromatography. In
the present study, we developed and validated on reference
bacterial strains two duplex dipsticks. The ﬁrst, RDT1, detects
PS antigens speciﬁc to meningococcal serogroups A and
W135/Y. The second, RDT2, detects serogroups C and Y. The
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Figure 2. Predictive Values for N. meningitidis Diagnosis
PVPs and NPVs for the diagnosis of N. meningitidis serogroup A (A) and
serogroup W135 (B), according to prevalence. PVP is represented by the
purple line with open circles, and NPV by the blue line with filled circles.
DOI: 10.1371/journal.pmed.0030337.g002
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were 100%. On CSF specimens from Niger, the speciﬁcities
for serogroups A and W135 were excellent (97.1% and 99.3%
respectively), as were the sensitivities (93.6% and 100%,
respectively). Convincing diagnostic evidence is demonstrated
for these two major and epidemic prone serogroups in Africa,
by the positive and negative likelihood ratios of the tests.
The speciﬁcities of the RDTs for CSF infected with
serogroups C and Y were excellent, but both serogroups are
rare in Africa so we could not assess the sensitivity for
serogroup C, because no CSF samples of patients infected
with serogroup C were available; in addition, the sensitivity of
the tests for serogroup Y still needs to be determined more
accurately. Thus, usefulness of these RDTs is potentially
limited for Europe or the U.S., where serogroups C and B are
the main serogroups circulating. Further evaluation of the
diagnostic accuracy of the RDT serogroup C will be
conducted as well as a comparative study of both RDT1 and
RDT2 in developed countries context. In the future, we plan
to develop two other rapid tests for the detection of
serogroup B, and serogroup X, an emerging threat in the
African meningitis belt [5,31,32].
The immunochromatography dipstick RDTs described
here are simple to perform and can be used by health staff
in the ﬁeld. The detection limit of 1 ng PS/ml is similar to that
of ELISA assays and lower than that of latex agglutination
assays (10–100 ng PS/ml), explaining the higher speciﬁcities
and sensitivities of RDTs compared with the Pastorex
agglutination kit. In recent studies performed in Niger and
Burkina Faso under reference laboratory conditions and in a
district laboratory, the sensitivities and speciﬁcities of the
Pastorex kit for the diagnosis of serogroups A and W135 were
Se 84.9%–88% and Sp 93%–97.4% [13,14]. In contrast, the
RDTs described in this study had sensitivities and speciﬁcities
of, respectively, 93.8% and 97.1% for serogroup A and 100%
and 99.4% for serogroup W135.
Both the Pastorex kit and the RDTs detect serogroup
capsular PS antigen. The main advantages to detecting PS
antigen are its large amount in the CSF and blood of
meningitis patients and its stability to high temperature (even
boiling). RDT1 (A and W135/Y) and RDT2 (C and Y) were as
accurate and reliable at 25 8Ca sa t4 58C—the latter
corresponding to typical room temperature during the
meningitis season in the African meningitis belt. In most
endemic areas, storage at temperatures above 25 8C for some
length of time is unavoidable and should be taken into
account. Preliminary stability data for RDT1 and RDT2 at 60
8C for 3 wk suggests that the tests could be stored at 25 8C for
2 y, or be transported to and stored at room temperature for
some time in air-conditioned settings. Studies on improving
the stability of RDT2 for serogroup Y are ongoing. These
properties are of considerable importance for countries of
the African meningitis belt where the ambient temperature
ranges from 15 8Ct o4 58C according to the season. To
prevent degradation of RDTs on exposure to humidity during
the rainy season, they should be individually packaged in
moisture-proof envelopes that should remain sealed until
immediately prior to use.
PCR and RDT1 tests gave concordant results in 96.5% of
cases in a blind comparative study performed by two
technicians. The kappa coefﬁcient obtained in this study
was high (0.92), reﬂecting almost perfect agreement. The two
discordant results corresponded to two serogroup A CSF
specimens: one was negative with RDT1 but weakly positive
with PCR, and the second was strongly positive with RDT1 but
uninterpretable with PCR, due to the presence of inhibitors
(no ampliﬁcation of the positive control DNA). A large-scale
study comparing PCR and RDTs is warranted in the future,
since PCR detects DNA and RDTs detect PS antigen. Thus
RDTs may actually be more sensitive than PCR in patients
with prior antibiotic therapy, sample contamination, delays
in processing, or presence of PCR inhibitors.
Our RDTs are easier to perform than currently available
latex agglutination kits. They also give more rapid results and
discriminate more accurately between serogroups Y and
W135, using the second test (RDT2) as a control. The negative
and positive predictive values for the two main serogroups
involved in outbreaks in the meningitis belt (A and W135)
exceeded 95%, even for low prevalence of the disease. The
RDTs merit evaluation (i) with other types of clinical samples
(blood, urine) and on CSF samples of all serogroups from
patients from developed countries; (ii) in operational ﬁeld
conditions of health care centres in Africa during epidemic
and endemic periods; and (iii) on blood specimens of patients
undergoing antibiotic therapy. These tests represent a major
breakthrough for individual diagnosis and for surveillance of
meningococcal diseases in the African meningitis belt that
affect such a large proportion of meningitis patients in the
world. The development of RDTs for serogroup B and X is
ongoing, as well as for S. pneumoniae and H. inﬂuenzae b.
In order to make these RDTs available for supporting
further ﬁeld evaluation and epidemiological research, in-
house small-scale production is being implemented in
CERMES.
Supporting Information
Alternative Language Abstract S1. French Translation of the Abstract
Found at DOI: 10.1371/journal.pmed.0030337.sd001 (22 KB DOC).
Alternative Language Abstract S2. Spanish Translation of the
Abstract
Found at DOI: 10.1371/journal.pmed.0030337.sd002 (24 KB DOC).
Table 2. Comparative Results of RDT1 and PCR for CSF Samples
from Patients with Suspected Meningitis
RDT1 (A and W135/Y) Multiplex PCR (N. meningitidis,
S. pneumoniae, H. influenzae)
Negative
a Serogroup
A
Serogroup
W135/Y
Total
Negative 37 1
b 03 8
Serogroup A 1
c 16 0 17
Serogroup W135/Y 0 0 2 2
Total 38 17 2 57
Agreement between tests, 96.5% (55/57); Cohen’s kappa coefficient, 0.92 (0.82–1.03).
aClassified as ‘‘negative’’ for serogroup A or W135/Y. PCR results for these 37 CSF samples
were 16 negative, two N. meningitidis X, 16 S. pneumoniae, and four H. influenzae b.
bNegative by RDT1, weakly positive by PCR.
cStrongly positive by RDT1, noninterpretable by PCR (presence of inhibitors).
DOI: 10.1371/journal.pmed.0030337.t002
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Background Bacterial meningitis, a potentially deadly infection of
tissues that line the brain and spinal cord, affects over 1 million people
each year. Patients with bacterial meningitis usually have fever,
headache, and stiff neck, and may become unconscious and die if the
disease is not treated within hours. Most cases of bacterial meningitis
occur in Africa, particularly in the arid savannah region south of the
Sahara known as the Sahel, where epidemic outbreaks of meningitis
occur periodically. This region, also called the ‘‘meningitis belt,’’ extends
from Senegal and adjacent coastal countries in West Africa across the
continent to Ethiopia. Although most outbreaks tend to occur in the dry
season, they differ in frequency in different areas of the meningitis belt,
and may involve any of several kinds of bacteria. One of the major
causes of epidemic meningitis is Neisseria meningitidis, a meningococcus
bacterium that exists in several different groups. Group A has been a
common cause of epidemic meningitis in Africa, and some outbreaks
were due to group C. More recently, group W135 has emerged as an
epidemic strain. In addition to prompt diagnosis and treatment of
individual cases, effective public health strategies for controlling
meningococcal meningitis include rapid identification of outbreaks
and determination of the type of bacteria involved, followed by mass
vaccination of people in the surrounding area without delay. Vaccines
are chosen on the basis of the responsible meningococcal serogroup:
either the inexpensive bivalent vaccine A/C or the expensive, less readily
available trivalent vaccine A/C/W135. Before the advent of W135 as an
epidemic clone, bivalent vaccine was applied in the meningitis belt
without identification of the serogroup. With the appearance of the
W135 strain in 2003, however, the determination of serogroup before
vaccination is important to select an effective vaccine and avoid
misspending of limited funds.
Why Was This Study Done? Because there are few laboratories in the
affected countries and epidemiological surveillance systems are inad-
equate, it is difficult for health authorities to mount a rapid and effective
vaccination campaign in response to an outbreak. In addition, because
the two main bacteria (meningococcus and pneumococcus) that cause
meningitis require different antibiotic treatments, it is important for
doctors to find out quickly which bacteria is causing an individual case.
The authors of this study wanted to develop a rapid and easy test that
can tell whether meningococcus is the cause of a particular case of
meningitis, and if so, which group of meningococcus is involved. As most
outbreaks in the meningitis belt occur in rural areas that are distant from
well-equipped medical laboratories, it was necessary to develop a test
that can be carried out at the patient’s bedside by nurses, does not
require refrigeration or laboratory equipment, and is highly accurate in
distinguishing among the different groups of meningococcus.
What Did the Researchers Do and Find? The researchers have
developed a rapid test to determine whether a patient’s meningitis is
caused by one of the four most common groups of meningococcus
circulating in Africa. The test is done on the patient’s spinal fluid, which is
obtained by a lumbar puncture (spinal tap) as part of the usual
evaluation of a patient thought to have meningitis. The test uses two
paper strips, also called dipsticks (one for groups A and W135/Y, and the
other for groups C and Y), that can be placed in two separate tubes of
the patient’s spinal fluid. After several minutes, the appearance of red
lines on the dipsticks shows whether one of the four groups of
meningococcus is present. The dipsticks can be produced in large
quantities and relatively cheaply. The researchers showed that the test
dipsticks are stable for weeks in hot weather, and are therefore practical
for bedside use in resource-poor settings. They examined the test on
stored spinal fluid from patients in Niger and found that the dipstick test
was able to identify the correct group of meningococcus more than 95%
of the time for the three groups represented in these specimens (the
results were compared to a standard DNA test or culture that are highly
accurate for identifying the type of bacteria present but much more
complicated and expensive).
What Do These Findings Mean? The new dipstick test for meningo-
coccal meningitis represents a major advance for health-care workers in
remote locations affected by meningitis epidemics. This test can be
stored without refrigeration and used at bedside in the hot temperatures
typical of the African savannah during the meningitis season. The
dipsticks are easier to use than currently available test kits, give more
rapid results, and are more accurate in telling the difference between
group Y and the increasingly important group W135. Further research is
needed to determine whether the test can be used with other clinical
specimens (such as blood or urine), and whether the test is dependable
for detecting group C meningococcus, which is common in Europe but
rare in Africa. Nonetheless, the dipstick test promises to be an important
tool for guiding individual treatment decisions as well as public health
actions, including vaccine selection, against the perennial threat of
epidemic meningitis.
Additional Information. Please access these Web sites via the online
version of this summary at http://dx.doi.org/10.1371/journal.pmed.
0030337.
  World Health Organization fact sheet on meningococcal meningitis
  PATH Meningitis Vaccine Project
  US Centers for Disease Control and Prevention page on
meningococcal disease
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